Watson Biological Reorganization New Coronatte Virus Mutant Vaccine Obstacles Clinical Test Approval

According to the news of the Financial Association on September 1st, Yunnan Watson Biotechnology Co., Ltd. issued an announcement that the company and subsidiary Shanghai Zirun and Beijing Watson Innovation Biotechnology Co., Ltd. jointly developed "Reorganized New Coronary Virus Virus Vapfulness (CHO cells ) "Recently received the" Pharmaceutical Clinical Test Approval "approved by the State Drug Administration. On the same day, the "new coronary virus mutant mRNA vaccine (S protein chimeric)" jointly developed by the company and Shanghai Bluebird and Shanghai Bluebird has recently obtained the "Pharmaceutical Clinical Test approval" approved by the State Drug Administration.

According to public information, Yunnan Watson Biotechnology Co., Ltd. was established in 2001. The headquarters is located in the Kunming High -tech Zone. It is a high -tech biopharmaceutical company specializing in the research and development, production, and sales of biotechnology and drug collection of people. The field of biotechnology drugs represented by new vaccines is in the leading position of the industry. In 2010, the company was successfully listed on the Shenzhen Stock Exchange (stock code: 300142), becoming the first enterprise listed on the China GEM in Yunnan Province.

The company currently has 8 vaccine varieties (12 product regulations). It is the first manufacturer of 13 -valent pneumonia -pneuming vaccine in China, the world's second self -developed and successful listing of 13 -valent pneumonia. Manufacturers of vaccines and HPV vaccines. The company has established a leading domestic vaccine research and development and industrialization technology platform, and has established close cooperative relationships with many domestic research institutes, universities and Gates Foundation and other international institutions.

The company has invested in the establishment of a product R & D center located in the Kunming National High -tech Zone, Shanghai Zhangjiang, and a modern vaccine production base located in Yuxi National High -tech Zone in Yunnan. At the same time, it is building a vaccine industrialization technology innovation center and industrialization base in Beijing, Guangdong, Chengdu and other places.

Smart bud data shows that Yunnan Watson Biotechnology Co., Ltd. and its related companies have applied for more than 160 patents, of which more than 120 invention patents, accounting for more than 75%. Except for China, the company has a patented technology layout in Europe, India, the United States, Brazil and other countries/regions. By further analyzing its patented technology data, the company's patented technology is mainly deployed in human papilloma virus, immunogenicity, macromolecular, yeast cells, shell protein and other fields.

- END -